Esperion Therapeutics, Inc. (NASDAQ:ESPR) Given Consensus Rating of “Moderate Buy” by Analysts

Shares of Esperion Therapeutics, Inc. (NASDAQ:ESPR) have been assigned a consensus recommendation of “Moderate Buy” from the seven research firms that are covering the firm, Marketbeat reports. One equities research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation, four have given a buy recommendation and one has issued a strong buy recommendation on the company. The average 1 year price target among analysts that have covered the stock in the last year is $5.54.

Several research analysts have recently weighed in on the company. Weiss Ratings restated a “sell (d-)” rating on shares of Esperion Therapeutics in a research note on Tuesday, April 21st. Wall Street Zen raised Esperion Therapeutics from a “hold” rating to a “buy” rating in a report on Saturday, March 14th. Needham & Company LLC lifted their price objective on Esperion Therapeutics from $4.00 to $5.00 and gave the stock a “buy” rating in a report on Tuesday, March 3rd. HC Wainwright reaffirmed a “neutral” rating and issued a $3.16 price objective on shares of Esperion Therapeutics in a report on Friday. Finally, Citizens Jmp lifted their price objective on Esperion Therapeutics from $4.00 to $5.00 and gave the stock a “market outperform” rating in a report on Friday, March 13th.

Hedge Funds Weigh In On Esperion Therapeutics

Hedge funds have recently made changes to their positions in the business. JPMorgan Chase & Co. boosted its stake in shares of Esperion Therapeutics by 68.4% in the third quarter. JPMorgan Chase & Co. now owns 945,491 shares of the biopharmaceutical company’s stock worth $2,506,000 after acquiring an additional 384,095 shares during the period. AIGH Capital Management LLC bought a new position in shares of Esperion Therapeutics in the third quarter worth about $7,950,000. Royce & Associates LP purchased a new stake in Esperion Therapeutics during the third quarter valued at approximately $6,078,000. Integral Health Asset Management LLC purchased a new stake in Esperion Therapeutics during the third quarter valued at approximately $3,975,000. Finally, Quantbot Technologies LP purchased a new stake in Esperion Therapeutics during the third quarter valued at approximately $476,000. Institutional investors own 47.39% of the company’s stock.

Key Esperion Therapeutics News

Here are the key news stories impacting Esperion Therapeutics this week:

• Positive Sentiment: Archimed agreed to acquire Esperion in a deal valuing the company at as much as ~$1.1 billion; shareholders are to receive $3.16 per share in cash plus the right to participate in up to $100 million of contingent milestone payments — the bid is the primary catalyst lifting the stock. Article Title Article Title
• Neutral Sentiment: HC Wainwright reaffirmed a “neutral” rating and set a $3.16 price target — the PT matches the deal cash price, effectively signaling analyst alignment with the offer price but leaving little upside under the transaction. Article Title
• Neutral Sentiment: Trading was temporarily halted ahead of the announcement for “news pending,” consistent with a material corporate event; halts are routine but can compress post‑halt volatility. (Internal trading halt notice)
• Neutral Sentiment: Unusual options activity: roughly 7,568 calls were bought — about a 212% increase versus typical daily call volume — indicating speculative or arbitrage positioning around the deal. This can amplify intraday moves but doesn’t change deal economics. (Options flow report)
• Negative Sentiment: Multiple shareholder‑rights law firms (Monteverde & Associates/M&A Class Action Firm, Ademi LLP, and Halper Sadeh LLC) have opened investigations alleging Esperion shareholders may not be receiving a fair price, which could lead to litigation, a negotiated price revision, or delays to closing. Article Title Article Title Article Title

Esperion Therapeutics Price Performance

ESPR stock opened at $3.11 on Friday. Esperion Therapeutics has a 1-year low of $0.69 and a 1-year high of $4.18. The business has a fifty day moving average price of $2.55 and a 200-day moving average price of $3.07. The stock has a market capitalization of $800.53 million, a P/E ratio of -18.29, a P/E/G ratio of 1.62 and a beta of 1.17.

Esperion Therapeutics (NASDAQ:ESPR) last posted its quarterly earnings results on Tuesday, March 10th. The biopharmaceutical company reported $0.22 earnings per share for the quarter, missing the consensus estimate of $0.23 by ($0.01). The firm had revenue of $168.45 million during the quarter, compared to analysts’ expectations of $165.12 million. As a group, analysts anticipate that Esperion Therapeutics will post 0.05 earnings per share for the current year.

About Esperion Therapeutics

Esperion Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of oral, low–density lipoprotein cholesterol (LDL-C)–lowering therapies. The company’s research and development efforts center on small-molecule compounds designed to address atherosclerotic cardiovascular disease by targeting cholesterol biosynthesis pathways. Esperion seeks to provide novel treatment options for patients who require additional LDL-C reduction beyond what is achieved with statins or who are statin-intolerant.

The company’s lead products include NEXLETOL (bempedoic acid), an oral adenosine triphosphate–citrate lyase (ACL) inhibitor approved by the U.S.